A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
Patrick Y. Wen
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Stemline Therapeutics
Honoraria - Stemline Therapeutics
Surasak Phuphanich
No relevant relationships to disclose
Robert Aiken
No relevant relationships to disclose
Joseph C. Landolfi
No relevant relationships to disclose
William T. Curry
No relevant relationships to disclose
Jay-Jiguang Zhu
No relevant relationships to disclose
Michael J. Glantz
Research Funding - ImmunoCellular Therapeutics
David M. Peereboom
No relevant relationships to disclose
James Markert
No relevant relationships to disclose
Renato V. LaRocca
No relevant relationships to disclose
Donald O'Rourke
No relevant relationships to disclose
Karen L. Fink
No relevant relationships to disclose
Lyndon J. Kim
No relevant relationships to disclose
Michael L. Gruber
No relevant relationships to disclose
Glenn Jay Lesser
Honoraria - Merck
Edward Pan
No relevant relationships to disclose
Santosh Kesari
No relevant relationships to disclose
Elma S. Hawkins
Consultant or Advisory Role - ImmunoCellular Therapeutics
John Yu
Employment or Leadership Position - ImmunoCellular Therapeutics; ImmunoCellular Therapeutics; ImmunoCellular Therapeutics
Stock Ownership - ImmunoCellular Therapeutics